Navigation Links
Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Date:5/8/2008

of California, Irvine. "We are encouraged that in the long-term trial, asenapine had a lower incidence of clinically significant weight gain (15%) vs olanzapine (36%)."

Presentation of the overview of the Olympia Program in schizophrenia (oral abstract #80) is on Thursday, May 8, at 11:00 am in Room 101.

Long-term Safety and Efficacy Data

In a year long, double-blind, randomized study of 1200 patients with schizophrenia or schizoaffective disorder treated with asenapine or olanzapine (3:1 randomization), the safety evaluation showed that the overall rates of AEs were similar for the asenapine 5-10 mg BID arm and olanzapine 10-20 mg QD arm (drug-related AEs, 60 percent and 61 percent respectively; withdrawal due to serious adverse events, 6.3 percent and 6.8 percent, respectively). On efficacy measures, improvements in PANSS total score were greatest for both asenapine and olanzapine within the first six to eight weeks of treatment and were maintained throughout the 52-week study period. In an exploratory secondary analysis, the between-group difference at 52 weeks favored olanzapine. Most commonly reported AEs (greater than or equal to 10 percent) in both treatment groups were insomnia, worsening psychotic symptoms, weight gain and depression.

Additional Asenapine Data Presentations

Additional asenapine data were presented in poster sessions during the meeting.

About Bipolar Disorder

Bipolar disorder, commonly referred to as manic-depressive disorder, is a chronic, episodic illness characterized by mania (episodes of elevated moods, extreme irritability, and increased energy), depression (overwhelming feelings of sadness, suicidal thoughts), or a combination of both. It affects approximately 1 to 5 percent of adults, including more than 10 million adults in the U.S. and more than four million people in Europe.(2,3,4) The condition can start early in childhood or later in life, with the average age of onset between 15
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014 A new Manhattan ... Decision Makers 2014, finds that members of ... care organizations (MCOs) and pharmacy benefits managers (PBMs) ... information.  A majority of formulary decision makers report ... during the formulary decision making process today than ...
(Date:7/14/2014)... July 14, 2014  Clinicians at a leading ... have become the first in the country to ... using an upgraded Clinac® medical linear accelerator from ... been enhanced with High Intensity Mode dose delivery ... Institute to shorten treatment times and deliver stereotactic ...
(Date:7/14/2014)... FAIRHOPE, Ala. , July 14, 2014  Patients ... of patients as Express Scripts and other major pharmacy ... coverage. The cuts will directly impact millions of patients ... of medical conditions, including persistent pain from cancer, diabetes ... will begin notifying some patients on July 15. ...
Breaking Medicine Technology:Digital Resources Play Critical Role in Formulary Decision Making 2Digital Resources Play Critical Role in Formulary Decision Making 3Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 2Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 2Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 4
... WASHINGTON, Nov. 20 Pharmaceutical,researchers are testing 92 ... related conditions, according to a report released today ... December,1 marks the 20th anniversary of "World AIDS ... the 1988 World Summit of Ministers of Health ...
... in Non-Small Cell Lung Cancer Expected to Inform ... for Experimental Cancer Treatment, MOUNTAIN VIEW, Calif., ... a leading provider of software,strategic consulting, and regulatory ... its Strategic Consulting Services Group,is using a quantitative ...
Cached Medicine Technology:92 Medicines and Vaccines now in Development for HIV/AIDS 292 Medicines and Vaccines now in Development for HIV/AIDS 3Pharsight Uses FDA Disease Model to Support Oncology Drug Development 2Pharsight Uses FDA Disease Model to Support Oncology Drug Development 3
(Date:7/14/2014)... Europe’s market for cardiac surgery devices ... by 2020, with the transcatheter heart valve devices sector ... transcatheter mitral valve repair (TMVR) segments) fuelling this growth. ... ?urrently the only THVI product on the market. However, ... and are anticipated to get CE approval by end-2020. ...
(Date:7/14/2014)... Since the announcement of the merger to form AAG HealthGAINS ... has been traveling to our network of facilities nationwide to ... our proprietary Maximum Sexual Performance Program for men and women. ... location on July 22nd, AAG Health NYC, 65 Broadway, Suite ... train our staff, and be on hand to answer patient ...
(Date:7/14/2014)... The North America Biostimulant Market report defines and ... and forecast of revenue. The biostimulants market in North ... in 2013 to $490.1 million by 2018, at a ... through the TOC of the North America Biostimulant Market ... provided. This also provides a glimpse of the segmentation ...
(Date:7/14/2014)... 14, 2014 Employers looking to ... employees with more benefit options must understand how ... online marketplaces, are the future of employee benefits. ... Jersey (Horizon BCBSNJ) is offering a free webinar, ... Offering More Options, to demonstrate how HorizonSelect, its ...
(Date:7/14/2014)... Continuing a steady trend of growth ... the heels of first-quarter success with Orange Regional Medical ... company founded by CEO and President Dr. Virginia Feldman ... three new members. Robert Poltenovage has joined ... John Steele, LPN and Angelica D’Amico have joined the ...
Breaking Medicine News(10 mins):Health News:Europe Cardiac Surgery Device Market Value to Go Beyond USD 3.4 Bn by 2020, According to iData Research Study Available at MarketPublishers.com 2Health News:Europe Cardiac Surgery Device Market Value to Go Beyond USD 3.4 Bn by 2020, According to iData Research Study Available at MarketPublishers.com 3Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 2Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 3Health News:No Cost Employer Webinar to Demonstrate How Private Exchanges Can Lower Benefit Costs While Increasing Options for Employees 2Health News:Nexus Health Resources Continues Growth, Outstanding Health Care Coordination With Addition of Three New Team Members 2
... carcinoma in situDCISwho later develop invasive breast cancer in ... from breast cancer than those who do not develop ... 11 in the Journal of the National Cancer ... have compared breast conserving surgery (lumpectomy) to mastectomy and ...
... , FRIDAY, March 11 (HealthDay News) -- Taking ... but mostly in people at increased risk for the ... in their blood, according to a new study. ... or other nonsteroidal anti-inflammatory drugs (NSAIDs) have a reduced ...
... March 11 (HealthDay News) -- Watching your team win a ... be thrilling, but there may be a drawback: aggressive, testosterone-fueled ... found that traffic deaths at the game site and the ... game is over. Researchers at North Carolina State University ...
... are a burning issue. A straightforward guide to a closer understanding ... 2011). The Dose Makes the Poison: A Plain-Language Guide to Toxicology, ... leads to a distortion in many people,s conceptions of toxins and ... We are exposed to media reports on a daily basis of ...
... DETROIT Theories have long proposed that testosterone influences ... a recent study at Wayne State University give a ... mating behavior, and how testosterone is associated with dominance ... of an attractive woman. The study engaged ...
... causes AIDS invades human immune cells and causes ... can then infect new cells. A research team led ... Priv.-Doz. Dr. Barbara Mller of Heidelberg University Hospital have ... infected cell in virion release, and discovered that the ...
Cached Medicine News:Health News:DCIS patients who get invasive breast cancer have higher mortality 2Health News:Aspirin May Protect Against Colorectal Cancer -- But Only in Certain People 2Health News:Fans of Winning Teams Linked to Fatal Crashes 2Health News:'The Dose Makes the Poison: A Plain-Language Guide to Toxicology,' 3rd Edition 2Health News:Wayne State study links testosterone with men's ability to 'woo' potential mates 2Health News:Pushing HIV out the door: How host factors aid in the release of HIV particles 2
LCD monitors....
This monitor is designed specifically for medical applications and is UL2601-1 listed....
Standard arthroscope with telescope (4 mm) for large joints....
A lower cost alternative to the flagship A3, the A1 retains the essential characteristics of high quality image, simplicity of operation and reliability....
Medicine Products: